Label expansion for evaporative dry eye due to MGD will support further efforts to drive patient access to insurance-covered TearCare treatments MENLO PARK, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- ...
A systematic review found that there were currently a limited number of clinical trials evaluating treatment for dry eye disease (DED) that is associated with meibomian gland dysfunction (MGD). Future ...
Meibomian gland dysfunction (MGD) is underdiagnosed and undertreated, with asymptomatic disease far more common than symptomatic disease. As the condition progresses, patients who were initially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback